drugset / Trial / NCT00987558

Effect of Repeated Administration of Eslicarbazepine Acetate on the Pharmacokinetics of Simvastatin in Healthy Subjects

NCT00987558

Phase 1 Completed 30 enrolled Bial - Portela C S.A.
RandomizedCrossoverOpen-labelTreatment

Summary

The primary objective was to investigate whether multiple-dose administration of ESL 800 mg once daily affects the pharmacokinetics of simvastatin, a substrate of CYP34A.

Timeline

Start
2009-06
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown 800 mg Oral
Subject Simvastatin Small molecule 80 mg Oral

Indications